Potential for diagnosis versus therapy monitoring of attention deficit hyperactivity disorder: a new epigenetic biomarker interacting with both genotype and auto-immunity
Authors:
- Walter AdrianiWAWalter Adriani
- Emilia RomanoEREmilia Romano
- Mariangela PucciMariangela Pucci
- Esterina PascaleEsterina Pascale
- Luca CernigliaLuca Cerniglia
- Silvia CiminoSilvia Cimino
- Renata TambelliRTRenata Tambelli
- Paolo CuratoloPCPaolo Curatolo
- Oleg GranstremOGOleg Granstrem
- Mauro MaccarroneMMMauro Maccarrone
- Giovanni LaviolaGiovanni Laviola
- Claudio D’aDdarioClaudio D’aDdario
- 18 August 2017
- journal article
- research article
- Published by Springer Nature in European Child & Adolescent Psychiatry
- Vol. 27 (2) , 241-252
Abstract
In view of the need for easily accessible biomarkers, we evaluated in ADHD children the epigenetic status of the 5′-untranslated region (UTR) in the SLC6A3 gene, coding for human dopamine transporter (DAT). We analysed buccal swabs and sera from 30 children who met DSM-IV-TR criteria for ADHD, assigned to treatment according to severity. Methylation levels at six-selected CpG sites (among which, a CGGCGGCGG and a CGCG motif), alone or in combination with serum titers in auto-antibodies against dopamine transporter (DAT aAbs), were analysed for correlation with CGAS scores (by clinicians) and Conners’ scales (by parents), collected at recruitment and after 6 weeks. In addition, we characterized the DAT genotype, i.e., the variable number tandem repeat (VNTR) polymorphisms at the 3′-UTR of the gene. DAT methylation levels were greatly reduced in ADHD patients compared to control, healthy children. Within patients carrying at least one DAT 9 allele (DAT 9/x), methylation at positions CpG2 and/or CpG6 correlated with recovery, as evident from delta-CGAS scores as well as delta Conners’ scales (‘inattentive’ and ‘hyperactive’ subscales). Moreover, hypermethylation at CpG1 position denoted severity, specifically for those patients carrying a DAT 10/10 genotype. Intriguingly, high serum DAT-aAbs titers appeared to corroborate indications from high CpG1 versus high CpG2/CpG6 levels, likewise denoting severity versus recovery in DAT 10/10 versus 9/x patients, respectively. These profiles suggest that DAT 5′UTR epigenetics plus serum aAbs can serve as suitable biomarkers, to confirm ADHD diagnosis and/or to predict the efficacy of treatment.Keywords
Funding Information
- Ministero della Salute ("Under 40" call 2007; "ADHD-sythe", Italian partner, ERA-NET "PrioMedChild")
- FP7 Science (biomedicine) (BE) (Italian partner, project "EMTICS", Italian partner, project "MATRICS")
This publication has 85 references indexed in Scilit:
- Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDIINeuropsychopharmacology, 2012
- Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitisThe Lancet Neurology, 2011
- Disease-relevant autoantibodies in first episode schizophreniaJournal of Neurology, 2010
- The immunoregulatory role of dopamine: An updateBrain, Behavior, and Immunity, 2010
- Genetic Control of Individual Differences in Gene-Specific Methylation in Human BrainThe American Journal of Human Genetics, 2010
- Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigenThe Lancet Neurology, 2010
- AMPA receptor antibodies in limbic encephalitis alter synaptic receptor locationAnnals of Neurology, 2009
- Allele-specific gene expression patterns in primary leukemic cells reveal regulation of gene expression by CpG site methylationGenome Research, 2008
- Epigenomic Profiling Reveals DNA-Methylation Changes Associated with Major PsychosisThe American Journal of Human Genetics, 2008
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004